TG Therapeutics will hold a conference call on November 3, 2025, to discuss Q3 results and future outlook.
Quiver AI Summary
TG Therapeutics, Inc. will hold a conference call on November 3, 2025, at 8:30 AM ET to discuss its third-quarter results for 2025 and the business outlook for the remainder of the year. The call will be hosted by Chairman and CEO Michael S. Weiss, and participants can join via specific phone numbers or through a live webcast on the company’s website. An audio recording will also be available for replay for 30 days after the call. The company plans to release its financial results prior to the call. TG Therapeutics focuses on developing treatments for B-cell diseases and has FDA approval for BRIUMVI® for specific types of multiple sclerosis. More information is available on the company's website and its social media channels.
Potential Positives
- TG Therapeutics is hosting a conference call to discuss their third-quarter results and business outlook, indicating transparency and proactive communication with investors.
- The company has received FDA approval for BRIUMVI® (ublituximab-xiiy), a significant milestone that enhances its portfolio in treating B-cell diseases.
Potential Negatives
- None
FAQ
When is the TG Therapeutics conference call scheduled?
The TG Therapeutics conference call is scheduled for Monday, November 3, 2025, at 8:30 AM ET.
How can I participate in the TG Therapeutics earnings call?
To participate, call 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) with the Conference Title: TG Therapeutics Earnings Call.
Is there a live webcast for the conference call?
Yes, a live webcast will be available on the Events page of TG Therapeutics' website in the Investors & Media section.
Where can I find TG Therapeutics’ financial results?
The financial results will be announced in a press release prior to the conference call on TG Therapeutics' website.
What is BRIUMVI and its significance?
BRIUMVI® is an FDA-approved treatment for adult patients with relapsing forms of multiple sclerosis, developed by TG Therapeutics.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TGTX Insider Trading Activity
$TGTX insiders have traded $TGTX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TGTX stock by insiders over the last 6 months:
- SAGAR LONIAL sold 20,852 shares for an estimated $672,268
- YANN ECHELARD sold 10,000 shares for an estimated $369,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TGTX Hedge Fund Activity
We have seen 177 institutional investors add shares of $TGTX stock to their portfolio, and 175 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 2,677,500 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $96,363,225
- 1832 ASSET MANAGEMENT L.P. removed 1,339,800 shares (-90.3%) from their portfolio in Q2 2025, for an estimated $48,219,402
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,157,016 shares (+296.3%) to their portfolio in Q2 2025, for an estimated $41,641,005
- POINT72 ASSET MANAGEMENT, L.P. added 717,510 shares (+inf%) to their portfolio in Q2 2025, for an estimated $25,823,184
- BALYASNY ASSET MANAGEMENT L.P. added 696,125 shares (+inf%) to their portfolio in Q2 2025, for an estimated $25,053,538
- MORGAN STANLEY removed 647,935 shares (-31.6%) from their portfolio in Q2 2025, for an estimated $23,319,180
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 602,768 shares (-21.2%) from their portfolio in Q2 2025, for an estimated $21,693,620
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TGTX Analyst Ratings
Wall Street analysts have issued reports on $TGTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/06/2025
- B. Riley Securities issued a "Buy" rating on 09/17/2025
To track analyst ratings and price targets for $TGTX, check out Quiver Quantitative's $TGTX forecast page.
$TGTX Price Targets
Multiple analysts have issued price targets for $TGTX recently. We have seen 2 analysts offer price targets for $TGTX in the last 6 months, with a median target of $57.5.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $60.0 on 10/06/2025
- Mayank Mamtani from B. Riley Securities set a target price of $55.0 on 09/17/2025
Full Release
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com . An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com , for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit
www.tgtherapeutics.com,
and follow us on X (formerly Twitter)
@TGTherapeutics
and on
LinkedIn
.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor
Relations
Email:
[email protected]
Telephone: 1.877.575.TGTX (8489), Option 4
Media
Relations:
Email:
[email protected]
Telephone: 1.877.575.TGTX (8489), Option 6
